Feline Vascular Endothelial Growth Factor A (VEGF-A) is a member of the vascular endothelial growth factor (VEGF) family, which includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF)—key regulators of angiogenesis and vascular development. In cats (Felis catus), VEGF-A is produced by a variety of cells including endothelial cells, macrophages, fibroblasts, epithelial cells, and tumor cells, particularly in response to hypoxia, inflammation, or tissue injury. VEGF-A exerts its biological effects primarily through binding to VEGF receptor-1 (VEGFR-1/Flt-1) and VEGF receptor-2 (VEGFR-2/KDR) on endothelial cells, activating intracellular signaling pathways such as MAPK/ERK, PI3K/AKT, and PLCγ, which promote endothelial cell proliferation, migration, vascular permeability, and new blood vessel formation. In feline physiology, VEGF-A plays important roles in normal vascular development, wound healing, and tissue repair. Dysregulated VEGF-A expression is associated with tumor angiogenesis in feline cancers, including mammary carcinoma, squamous cell carcinoma, and lymphoma, where increased VEGF signaling supports tumor growth and metastasis by promoting blood vessel formation. Because angiogenesis is a key process in both cancer progression and tissue regeneration, feline VEGF-A is studied in veterinary oncology, vascular biology, and regenerative medicine, contributing to understanding of angiogenic signaling and potential therapeutic targets in cats.